fmc63 Search Results


93
Miltenyi Biotec rea1297
Rea1297, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fmc63/CD19+CAR+FMC63+Idiotype+Antibody%2C+REAfinity/10__1172_slash_jci173096-244-28-29
Average 93 stars, based on 1 article reviews
rea1297 - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

95
ACROBiosystems anti human fmc63 scfv
Anti Human Fmc63 Scfv, supplied by ACROBiosystems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fmc63/FITC-Labeled+Monoclonal+Anti-FMC63+scFv+Antibody%2C+Mouse+IgG1+(Y45)+DMF+Filed/pm42805174-813-6-10
Average 95 stars, based on 1 article reviews
anti human fmc63 scfv - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

91
Novus Biologicals fmc63 cd19
Figure 3. Immunophenotyping of 1D3-CD19CAR- GFP (blue, circle), <t>FMC63-CD19CAR-GFP</t> (red, square), or control (GFP only, green, triangle) trans- duced T cells in peripheral blood of treated mice Values shown are the percentage of total CD3+, CD90.2+
Fmc63 Cd19, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fmc63/CD19+Antibody+(FMC63)+%5BPE%5D/pm35755944-198-39-45
Average 91 stars, based on 1 article reviews
fmc63 cd19 - by Bioz Stars, 2026-11
91/100 stars
  Buy from Supplier

93
Novus Biologicals il 10
Figure 3. Immunophenotyping of 1D3-CD19CAR- GFP (blue, circle), <t>FMC63-CD19CAR-GFP</t> (red, square), or control (GFP only, green, triangle) trans- duced T cells in peripheral blood of treated mice Values shown are the percentage of total CD3+, CD90.2+
Il 10, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fmc63/CD19+Antibody+(FMC63)+-+Azide+and+BSA+Free/pm40721618-59-7-20
Average 93 stars, based on 1 article reviews
il 10 - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

93
Miltenyi Biotec cd19 car fmc63 idiotype antibody apc
Univariate analysis of ICANS.
Cd19 Car Fmc63 Idiotype Antibody Apc, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fmc63/CD19+CAR+FMC63+Idiotype+Antibody%2C+REAfinity/pmc09886226-98-5-10
Average 93 stars, based on 1 article reviews
cd19 car fmc63 idiotype antibody apc - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

95
ACROBiosystems mouse igg1 y45

Mouse Igg1 Y45, supplied by ACROBiosystems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fmc63/PE-Labeled+Monoclonal+Anti-FMC63+scFv+Antibody%2C+Mouse+IgG1+(Y45)+(Site-specific+conjugation)+DMF+Filed/pmc09826863-2-5-9
Average 95 stars, based on 1 article reviews
mouse igg1 y45 - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

90
Kite Pharma cdl (anti-fmc63 scfv) mouse mab

Cdl (Anti Fmc63 Scfv) Mouse Mab, supplied by Kite Pharma, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fmc63/fmc63+28z+car/pmc10862257-64-26-12
Average 90 stars, based on 1 article reviews
cdl (anti-fmc63 scfv) mouse mab - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Acrobio Healthcare Inc antibody fmc63 clone y45

Antibody Fmc63 Clone Y45, supplied by Acrobio Healthcare Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fmc63/anti+cd19++fmc63++car+immunogenicity+elisa+kit/pm37037829-368-11-17
Average 90 stars, based on 1 article reviews
antibody fmc63 clone y45 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
GenScript corporation cd19 car-t dna fragments

Cd19 Car T Dna Fragments, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fmc63/anti+fmc63+idiotype+antibody/10__1080_slash_2162402x__2022__2114740-73-37-56
Average 90 stars, based on 1 article reviews
cd19 car-t dna fragments - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Celgene activin receptor-igg1
Biopharmaceuticals and their clinical indications approved by the FDA in 2018–2020 [ <xref ref-type= 31 ]." width="250" height="auto" />
Activin Receptor Igg1, supplied by Celgene, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fmc63/fmc63+igg1/pmc07762162-25-4-15
Average 90 stars, based on 1 article reviews
activin receptor-igg1 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Absolute Biotech Inc cd19-migg2a (fmc63) (ab00613-2.0)
EGFR expression is elevated in CRC tumors and anti-EGFR Ab treatment reduces fecal occult blood levels in AOM/DSS-treated mice. ( a ) Schematic overview of induction of colitis-driven colorectal carcinomas by AOM/DSS treatment in female C57BL/6J mice ( n = 88) between days 0 and 70. Control mice received PBS instead of AOM/DSS ( n = 19) between days 0 and 70. At day 70, indicator mice ( n = 9 AOM/DSS-treated; n = 8 PBS-treated) were sacrificed and tissues were sampled for further analysis. Remaining AOM/DSS-treated mice were further subdivided at day 70 into two different dietary intervention groups receiving control diet (CD; n = 39) or glucose-free, high-protein diet (GFHPD; n = 40) until day 126. Dietary interventions were performed in the presence or absence of weekly intraperitoneal ( i.p. ) application of PBS ( n = 9 CD; n = 9 GFHPD), anti-EGFR Ab ( n = 15 CD; n = 16 GFHPD) or a ctrl. antibody ( n = 15 CD; n = 15 GFHPD) between day 70 and 126. PBS-treated control mice were fed either CD ( n = 5) or GFHPD ( n = 6) between day 70 and 126. AOM = azoxymethane; DSS = dextran sodium sulfate; anti-EGFR-mAb = <t>7A7-mIgG2a;</t> isotype ctrl. mAb = irrelevant mIgG2a; mAb = monoclonal Ab. ( b ) Concentration-dependent binding of anti-EGFR-mIgG2a or ctrl.-mIgG2a to recombinant murine EGFR was analyzed by ELISA experiments. Mean ± SEM of three independent experiments is presented. ( c ) Disease activity index (DAI) of AOM/DSS-treated mice ( n = 88) from day 0 to 70. ( d ) Representative images of endoscopy analyses of AOM/DSS or PBS-treated indicator mice at day 70. ( e ) Egfr mRNA expression was quantified by qPCR and related to Actb mRNA expression in normal or tumor colonic tissues collected from AOM/DSS-treated mice at day 70. Grey dotted line indicates median values of PBS-treated control mice at day 70 (left panel). Representative images of immunohistochemistry staining of EGFR in paraffin-embedded normal and tumor colonic biopsies ( n = 3 each) were collected from AOM/DSS-treated mice at day 70 (right panel). Scale bar = 50 µM. ( f – h ) Body weight, food consumption, and water consumption were routinely monitored between days 70 and 126. ( i ) Fecal occult blood was determined every second day using a hemoccult test. Results are presented as the area under the curve (AUC) from analyzed mice. * p ≤ 0.05, ** p ≤ 0.01. **** p ≤ 0.0001.
Cd19 Migg2a (Fmc63) (Ab00613 2.0), supplied by Absolute Biotech Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fmc63/cd19+migg2a++fmc63+++ab00613+2+0++antibody/pmc08616508-63-0-6
Average 90 stars, based on 1 article reviews
cd19-migg2a (fmc63) (ab00613-2.0) - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Eurofins expect anti-cd19 (fmc63) car t test
EGFR expression is elevated in CRC tumors and anti-EGFR Ab treatment reduces fecal occult blood levels in AOM/DSS-treated mice. ( a ) Schematic overview of induction of colitis-driven colorectal carcinomas by AOM/DSS treatment in female C57BL/6J mice ( n = 88) between days 0 and 70. Control mice received PBS instead of AOM/DSS ( n = 19) between days 0 and 70. At day 70, indicator mice ( n = 9 AOM/DSS-treated; n = 8 PBS-treated) were sacrificed and tissues were sampled for further analysis. Remaining AOM/DSS-treated mice were further subdivided at day 70 into two different dietary intervention groups receiving control diet (CD; n = 39) or glucose-free, high-protein diet (GFHPD; n = 40) until day 126. Dietary interventions were performed in the presence or absence of weekly intraperitoneal ( i.p. ) application of PBS ( n = 9 CD; n = 9 GFHPD), anti-EGFR Ab ( n = 15 CD; n = 16 GFHPD) or a ctrl. antibody ( n = 15 CD; n = 15 GFHPD) between day 70 and 126. PBS-treated control mice were fed either CD ( n = 5) or GFHPD ( n = 6) between day 70 and 126. AOM = azoxymethane; DSS = dextran sodium sulfate; anti-EGFR-mAb = <t>7A7-mIgG2a;</t> isotype ctrl. mAb = irrelevant mIgG2a; mAb = monoclonal Ab. ( b ) Concentration-dependent binding of anti-EGFR-mIgG2a or ctrl.-mIgG2a to recombinant murine EGFR was analyzed by ELISA experiments. Mean ± SEM of three independent experiments is presented. ( c ) Disease activity index (DAI) of AOM/DSS-treated mice ( n = 88) from day 0 to 70. ( d ) Representative images of endoscopy analyses of AOM/DSS or PBS-treated indicator mice at day 70. ( e ) Egfr mRNA expression was quantified by qPCR and related to Actb mRNA expression in normal or tumor colonic tissues collected from AOM/DSS-treated mice at day 70. Grey dotted line indicates median values of PBS-treated control mice at day 70 (left panel). Representative images of immunohistochemistry staining of EGFR in paraffin-embedded normal and tumor colonic biopsies ( n = 3 each) were collected from AOM/DSS-treated mice at day 70 (right panel). Scale bar = 50 µM. ( f – h ) Body weight, food consumption, and water consumption were routinely monitored between days 70 and 126. ( i ) Fecal occult blood was determined every second day using a hemoccult test. Results are presented as the area under the curve (AUC) from analyzed mice. * p ≤ 0.05, ** p ≤ 0.01. **** p ≤ 0.0001.
Expect Anti Cd19 (Fmc63) Car T Test, supplied by Eurofins, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fmc63/expect+anti+cd19++fmc63++car+t+test/pmc11962766-29-7-3
Average 90 stars, based on 1 article reviews
expect anti-cd19 (fmc63) car t test - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

Image Search Results


Figure 3. Immunophenotyping of 1D3-CD19CAR- GFP (blue, circle), FMC63-CD19CAR-GFP (red, square), or control (GFP only, green, triangle) trans- duced T cells in peripheral blood of treated mice Values shown are the percentage of total CD3+, CD90.2+

Journal: Molecular therapy. Methods & clinical development

Article Title: Selective B cell depletion upon intravenous infusion of replication-incompetent anti-CD19 CAR lentivirus.

doi: 10.1016/j.omtm.2022.05.006

Figure Lengend Snippet: Figure 3. Immunophenotyping of 1D3-CD19CAR- GFP (blue, circle), FMC63-CD19CAR-GFP (red, square), or control (GFP only, green, triangle) trans- duced T cells in peripheral blood of treated mice Values shown are the percentage of total CD3+, CD90.2+

Article Snippet: In order to verify the ability for both the 1D3-and FMC63-CD19CAR to target the mouse CD19 antigen, the A20 cells were incubated with 10, 1, 0.1, 0.001, or 0 mg/mL of either the 1D3CD19-blocking antibody (152402, BioLegend) or the FMC63-CD19- Molecular Th blocking antibody (NBP2-52716, Novus Biologicals).

Techniques: Control

Univariate analysis of ICANS.

Journal: Frontiers in Immunology

Article Title: Peripheral blood cellular profile at pre-lymphodepletion is associated with CD19-targeted CAR-T cell-associated neurotoxicity

doi: 10.3389/fimmu.2022.1058126

Figure Lengend Snippet: Univariate analysis of ICANS.

Article Snippet: Cells were stained with the CD19 CAR FMC63 Idiotype antibody-APC (Miltenyi Biotec, Bergisch-Gladbach, Germany) following the manufacturer’s instruction.

Techniques: Biomarker Discovery

Journal: STAR Protocols

Article Title: Inducing T cell dysfunction by chronic stimulation of CAR-engineered T cells targeting cancer cells in suspension cultures

doi: 10.1016/j.xpro.2022.101954

Figure Lengend Snippet:

Article Snippet: PE-labeled Monoclonal Anti-FMC63 scFv Antibody, Mouse IgG1 (Y45) , Acro Biosystems , Cat# FM3-HPY53; RRID: AB_2921284.

Techniques: Recombinant, Reverse Transcription, Software, Pore Size, Flow Cytometry, Transfection

Biopharmaceuticals and their clinical indications approved by the FDA in 2018–2020 [ <xref ref-type= 31 ]." width="100%" height="100%">

Journal: Pharmaceutics

Article Title: Potential and Applications of Nanocarriers for Efficient Delivery of Biopharmaceuticals

doi: 10.3390/pharmaceutics12121184

Figure Lengend Snippet: Biopharmaceuticals and their clinical indications approved by the FDA in 2018–2020 [ 31 ].

Article Snippet: Reblozyl , Luspatercept , Activin receptor-igg1 , Fusion protein , Anemia with beta thalassemia , Celgene.

Techniques: Infection

EGFR expression is elevated in CRC tumors and anti-EGFR Ab treatment reduces fecal occult blood levels in AOM/DSS-treated mice. ( a ) Schematic overview of induction of colitis-driven colorectal carcinomas by AOM/DSS treatment in female C57BL/6J mice ( n = 88) between days 0 and 70. Control mice received PBS instead of AOM/DSS ( n = 19) between days 0 and 70. At day 70, indicator mice ( n = 9 AOM/DSS-treated; n = 8 PBS-treated) were sacrificed and tissues were sampled for further analysis. Remaining AOM/DSS-treated mice were further subdivided at day 70 into two different dietary intervention groups receiving control diet (CD; n = 39) or glucose-free, high-protein diet (GFHPD; n = 40) until day 126. Dietary interventions were performed in the presence or absence of weekly intraperitoneal ( i.p. ) application of PBS ( n = 9 CD; n = 9 GFHPD), anti-EGFR Ab ( n = 15 CD; n = 16 GFHPD) or a ctrl. antibody ( n = 15 CD; n = 15 GFHPD) between day 70 and 126. PBS-treated control mice were fed either CD ( n = 5) or GFHPD ( n = 6) between day 70 and 126. AOM = azoxymethane; DSS = dextran sodium sulfate; anti-EGFR-mAb = 7A7-mIgG2a; isotype ctrl. mAb = irrelevant mIgG2a; mAb = monoclonal Ab. ( b ) Concentration-dependent binding of anti-EGFR-mIgG2a or ctrl.-mIgG2a to recombinant murine EGFR was analyzed by ELISA experiments. Mean ± SEM of three independent experiments is presented. ( c ) Disease activity index (DAI) of AOM/DSS-treated mice ( n = 88) from day 0 to 70. ( d ) Representative images of endoscopy analyses of AOM/DSS or PBS-treated indicator mice at day 70. ( e ) Egfr mRNA expression was quantified by qPCR and related to Actb mRNA expression in normal or tumor colonic tissues collected from AOM/DSS-treated mice at day 70. Grey dotted line indicates median values of PBS-treated control mice at day 70 (left panel). Representative images of immunohistochemistry staining of EGFR in paraffin-embedded normal and tumor colonic biopsies ( n = 3 each) were collected from AOM/DSS-treated mice at day 70 (right panel). Scale bar = 50 µM. ( f – h ) Body weight, food consumption, and water consumption were routinely monitored between days 70 and 126. ( i ) Fecal occult blood was determined every second day using a hemoccult test. Results are presented as the area under the curve (AUC) from analyzed mice. * p ≤ 0.05, ** p ≤ 0.01. **** p ≤ 0.0001.

Journal: Cancers

Article Title: Colorectal Cancer Progression Is Potently Reduced by a Glucose-Free, High-Protein Diet: Comparison to Anti-EGFR Therapy

doi: 10.3390/cancers13225817

Figure Lengend Snippet: EGFR expression is elevated in CRC tumors and anti-EGFR Ab treatment reduces fecal occult blood levels in AOM/DSS-treated mice. ( a ) Schematic overview of induction of colitis-driven colorectal carcinomas by AOM/DSS treatment in female C57BL/6J mice ( n = 88) between days 0 and 70. Control mice received PBS instead of AOM/DSS ( n = 19) between days 0 and 70. At day 70, indicator mice ( n = 9 AOM/DSS-treated; n = 8 PBS-treated) were sacrificed and tissues were sampled for further analysis. Remaining AOM/DSS-treated mice were further subdivided at day 70 into two different dietary intervention groups receiving control diet (CD; n = 39) or glucose-free, high-protein diet (GFHPD; n = 40) until day 126. Dietary interventions were performed in the presence or absence of weekly intraperitoneal ( i.p. ) application of PBS ( n = 9 CD; n = 9 GFHPD), anti-EGFR Ab ( n = 15 CD; n = 16 GFHPD) or a ctrl. antibody ( n = 15 CD; n = 15 GFHPD) between day 70 and 126. PBS-treated control mice were fed either CD ( n = 5) or GFHPD ( n = 6) between day 70 and 126. AOM = azoxymethane; DSS = dextran sodium sulfate; anti-EGFR-mAb = 7A7-mIgG2a; isotype ctrl. mAb = irrelevant mIgG2a; mAb = monoclonal Ab. ( b ) Concentration-dependent binding of anti-EGFR-mIgG2a or ctrl.-mIgG2a to recombinant murine EGFR was analyzed by ELISA experiments. Mean ± SEM of three independent experiments is presented. ( c ) Disease activity index (DAI) of AOM/DSS-treated mice ( n = 88) from day 0 to 70. ( d ) Representative images of endoscopy analyses of AOM/DSS or PBS-treated indicator mice at day 70. ( e ) Egfr mRNA expression was quantified by qPCR and related to Actb mRNA expression in normal or tumor colonic tissues collected from AOM/DSS-treated mice at day 70. Grey dotted line indicates median values of PBS-treated control mice at day 70 (left panel). Representative images of immunohistochemistry staining of EGFR in paraffin-embedded normal and tumor colonic biopsies ( n = 3 each) were collected from AOM/DSS-treated mice at day 70 (right panel). Scale bar = 50 µM. ( f – h ) Body weight, food consumption, and water consumption were routinely monitored between days 70 and 126. ( i ) Fecal occult blood was determined every second day using a hemoccult test. Results are presented as the area under the curve (AUC) from analyzed mice. * p ≤ 0.05, ** p ≤ 0.01. **** p ≤ 0.0001.

Article Snippet: CD19-mIgG2a (FMC63) (Ab00613-2.0) , mouse , Absolute Antibody NA, Boston, MA, USA , .

Techniques: Expressing, Concentration Assay, Binding Assay, Recombinant, Enzyme-linked Immunosorbent Assay, Activity Assay, Immunohistochemistry, Staining

GFHPD and anti-EGFR Ab treatment reduce tumoral Pd-l1 expression and PD-1 expressing T cells. ( a – d ) QPCR analyses were performed to quantify mRNA expression level of Cd45 , Cd3e , Cd4 , Cd8a , Cd69 , Bcma , F4/80 , Ly6g , Pd-1 , Pd-l1 , Ctla4 , Cd80 , or Cd86 in colonic tissues collected from indicated treatment groups of AOM/DSS mice. Results are based on ΔCT calculation including relation to β-actin mRNA expression. Heatmap was generated based on normalized values (%) per transcript. The mean value per group is presented. n = 6–7 ctrl. Ab and CD; n = 6–7 anti-EGFR Ab and CD; n = 4–6 ctrl. Ab and GFHPD; n = 6–9 anti-EGFR Ab and GFHPD. Red dotted horizontal lines represent respective median values of PBS-treated control mice at day 126. ( e , f ) MC-38 cells were incubated in standard culture medium (25 mM glucose, 1% NEAA) or glucose-free plus 20% NEAA medium for 48 h. ( e ) Pd-l1 mRNA expression was quantified by qPCR experiments and related to Ubc mRNA expression ( n = 5 independent experiments), while ( f ) PD-L1 protein expression was analyzed by Western blot experiments. Alpha-Tubulin expression served as a loading control (representative images of n = 5 independent experiments). ( g ) MC-38 cells were incubated in standard culture medium (25 mM glucose, 1% NEAA) or in glucose-free plus 20% NEAA medium in the presence or absence of either the anti-EGFR Ab 7A7-mIgG2a or the irrelevant control Ab CD19-mIgG2a for 48 h. Pd-l1 mRNA expression was quantified by qPCR experiments and related to Ubc mRNA expression ( n = 3 independent experiments). ( h ) Representative images from spleens collected from AOM/DSS-treated mice at day 126. ( i ) Representative spleen lengths were measured for indicated treatment groups. n = 9 ctrl. Ab and CD; n = 9 anti-EGFR Ab and CD; n = 6 ctrl. Ab and GFHPD; n = 11 anti-EGFR Ab and GFHPD. Red dotted horizontal line represents median values of PBS-treated control mice at day 126. ( j ) QPCR analyses were performed to quantify mRNA expression levels of Cd45 , Ly6g , F4/80 , Bcma , Cd69 , Cd3e , Cd4 , Cd8a , Ctla4 , and Pd-1 in splenic tissues collected from indicated treatment groups of AOM/DSS mice. Results are based on 2 − ΔCT calculation, including relation to β-actin mRNA expression. Heatmap was generated based on normalized values (%) per transcript. The mean value per group is presented. n = 10 ctrl. Ab and CD; n = 10 anti-EGFR Ab and CD; n = 10 ctrl. Ab and GFHPD; n = 11 anti-EGFR Ab and GFHPD. ( k ) Splenic CD3e, PD-1, and F4/80 protein expression levels were determined by Western blot experiments. Alpha-Tubulin expression served as a loading control. ( l ) Densitometric analyses were performed using ImageJ software. n = 10 ctrl. Ab and CD; n = 10 anti-EGFR Ab and CD; n = 10 ctrl. Ab and GFHPD; n = 11 anti-EGFR Ab and GFHPD. ( m ) Splenic PD-1 protein expression was related to splenic CD3e protein expression. ( n ) Splenic PD-1 protein expression is displayed in relation to colorectal tumor scores (smaller tumor 0–3; larger tumor 4–5). * p ≤ 0.05, ** p ≤ 0.01, **** p ≤ 0.0001.

Journal: Cancers

Article Title: Colorectal Cancer Progression Is Potently Reduced by a Glucose-Free, High-Protein Diet: Comparison to Anti-EGFR Therapy

doi: 10.3390/cancers13225817

Figure Lengend Snippet: GFHPD and anti-EGFR Ab treatment reduce tumoral Pd-l1 expression and PD-1 expressing T cells. ( a – d ) QPCR analyses were performed to quantify mRNA expression level of Cd45 , Cd3e , Cd4 , Cd8a , Cd69 , Bcma , F4/80 , Ly6g , Pd-1 , Pd-l1 , Ctla4 , Cd80 , or Cd86 in colonic tissues collected from indicated treatment groups of AOM/DSS mice. Results are based on ΔCT calculation including relation to β-actin mRNA expression. Heatmap was generated based on normalized values (%) per transcript. The mean value per group is presented. n = 6–7 ctrl. Ab and CD; n = 6–7 anti-EGFR Ab and CD; n = 4–6 ctrl. Ab and GFHPD; n = 6–9 anti-EGFR Ab and GFHPD. Red dotted horizontal lines represent respective median values of PBS-treated control mice at day 126. ( e , f ) MC-38 cells were incubated in standard culture medium (25 mM glucose, 1% NEAA) or glucose-free plus 20% NEAA medium for 48 h. ( e ) Pd-l1 mRNA expression was quantified by qPCR experiments and related to Ubc mRNA expression ( n = 5 independent experiments), while ( f ) PD-L1 protein expression was analyzed by Western blot experiments. Alpha-Tubulin expression served as a loading control (representative images of n = 5 independent experiments). ( g ) MC-38 cells were incubated in standard culture medium (25 mM glucose, 1% NEAA) or in glucose-free plus 20% NEAA medium in the presence or absence of either the anti-EGFR Ab 7A7-mIgG2a or the irrelevant control Ab CD19-mIgG2a for 48 h. Pd-l1 mRNA expression was quantified by qPCR experiments and related to Ubc mRNA expression ( n = 3 independent experiments). ( h ) Representative images from spleens collected from AOM/DSS-treated mice at day 126. ( i ) Representative spleen lengths were measured for indicated treatment groups. n = 9 ctrl. Ab and CD; n = 9 anti-EGFR Ab and CD; n = 6 ctrl. Ab and GFHPD; n = 11 anti-EGFR Ab and GFHPD. Red dotted horizontal line represents median values of PBS-treated control mice at day 126. ( j ) QPCR analyses were performed to quantify mRNA expression levels of Cd45 , Ly6g , F4/80 , Bcma , Cd69 , Cd3e , Cd4 , Cd8a , Ctla4 , and Pd-1 in splenic tissues collected from indicated treatment groups of AOM/DSS mice. Results are based on 2 − ΔCT calculation, including relation to β-actin mRNA expression. Heatmap was generated based on normalized values (%) per transcript. The mean value per group is presented. n = 10 ctrl. Ab and CD; n = 10 anti-EGFR Ab and CD; n = 10 ctrl. Ab and GFHPD; n = 11 anti-EGFR Ab and GFHPD. ( k ) Splenic CD3e, PD-1, and F4/80 protein expression levels were determined by Western blot experiments. Alpha-Tubulin expression served as a loading control. ( l ) Densitometric analyses were performed using ImageJ software. n = 10 ctrl. Ab and CD; n = 10 anti-EGFR Ab and CD; n = 10 ctrl. Ab and GFHPD; n = 11 anti-EGFR Ab and GFHPD. ( m ) Splenic PD-1 protein expression was related to splenic CD3e protein expression. ( n ) Splenic PD-1 protein expression is displayed in relation to colorectal tumor scores (smaller tumor 0–3; larger tumor 4–5). * p ≤ 0.05, ** p ≤ 0.01, **** p ≤ 0.0001.

Article Snippet: CD19-mIgG2a (FMC63) (Ab00613-2.0) , mouse , Absolute Antibody NA, Boston, MA, USA , .

Techniques: Expressing, Generated, Incubation, Western Blot, Software

Details of applied primary and secondary antibodies.

Journal: Cancers

Article Title: Colorectal Cancer Progression Is Potently Reduced by a Glucose-Free, High-Protein Diet: Comparison to Anti-EGFR Therapy

doi: 10.3390/cancers13225817

Figure Lengend Snippet: Details of applied primary and secondary antibodies.

Article Snippet: CD19-mIgG2a (FMC63) (Ab00613-2.0) , mouse , Absolute Antibody NA, Boston, MA, USA , .

Techniques: Concentration Assay, Enzyme-linked Immunosorbent Assay